Catheter Precision Presents New Clinical Data for VIVO and LockeT Systems at Heart Rhythm Society Meeting
Key Insights
Catheter Precision presented new clinical data for both VIVO (search) and LockeT (search) systems at the 47th Annual Heart Rhythm Society (search) meeting, with over 10,000 professionals in attendance.
A novel study demonstrated VIVO (search)'s feasibility in using intracardiac electrodes rather than surface ECG to accurately identify ventricular tachycardia (search), potentially providing safer VT diagnosis.
New peer-reviewed publications validated both products, with LockeT (search) showing high procedural success in 139 patients and VIVO (search) accurately predicting arrhythmogenic substrate (search) in 31 patients.
Catheter Precision, Inc. (NYSE American: VTAK) showcased groundbreaking clinical data for its VIVO (search) and LockeT (search) systems at the 47th Annual Heart Rhythm Society (search) (HRS) meeting in Chicago, marking significant advances in cardiac electrophysiology technology. The conference, which brought together more than 10,000 professionals worldwide, featured the highest number of abstract submissions in HRS history.
Novel VIVO Technology Demonstrates Breakthrough in Ventricular Tachycardia Diagnosis
The company presented pioneering research on ventricular arrhythmia localization using implanted cardioverter defibrillator intracardiac electrogram recordings. This study represents the first demonstration of feasibility for using intracardiac electrodes rather than surface 12-lead ECG to accurately identify ventricular tachycardia (search) (VT). The research indicates that VIVO (search) may provide patients with safer VT diagnosis and enable treatment for a currently difficult-to-treat patient population.
Professor Tarvinder Dhanjal was invited to present during a core session highlighting VIVO (search)'s benefits for improved workflow and accurate localization to enhance identification of areas of interest for ventricular ablation procedures. The presentation emphasized how VIVO's real-time 3D mapping capabilities leverage recorded CIED and EKG data to create integrated models for accurate arrhythmia localization.
Peer-Reviewed Publications Validate Clinical Efficacy
Recent publications in leading electrophysiology journals have provided robust clinical validation for both products. The Journal of Cardiovascular Electrophysiology accepted a comprehensive study on LockeT (search) involving 139 patients, which concluded that the device demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following electrophysiology procedures requiring large-bore venous access (LBVA).
A separate VIVO (search) study published in EP Europace included 31 patients and mapped 48 VTs using both VIVO and standard electroanatomical mapping systems to determine accuracy. The study concluded that VIVO can accurately predict the arrhythmogenic substrate (search) for scar-dependent VT and that incorporation of VIVO mapping into conventional VT ablation workflows improves procedural efficiency.
Clinical Impact and Market Positioning
David Jenkins, CEO of Catheter Precision, emphasized the significance of the research validation: "Having an abstract accepted at any conference is an accomplishment. Somewhere around 50% of abstracts are accepted and knowing that this is the largest submission of ground-breaking data ever at HRS means that the research and products resonate with the abstract committee."
The LockeT (search) publication reinforces the device's position as a beneficial solution for physicians, patients, and hospitals. Jenkins noted that the peer-reviewed validation from a prestigious medical journal underscores the importance of the data and enables Catheter Precision to continue its mission of product innovation.
Technology Specifications and Regulatory Status
LockeT (search) is a suture retention device intended to assist in wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and holding CE Mark approval. VIVO (search) (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias (search) pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and holds the CE mark.
The company has recently engaged a strategic advisor to explore various options for its distinctive electrophysiology products, indicating potential expansion opportunities in both U.S. and European markets.